These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23336356)

  • 1. Prostacyclin withdrawal in pulmonary hypertension #264.
    Bartlett C; Landzaat L;
    J Palliat Med; 2013 Feb; 16(2):204-5. PubMed ID: 23336356
    [No Abstract]   [Full Text] [Related]  

  • 2. Transition from IV to subcutaneous prostacyclin: premature withdrawal?
    Shapiro S; Hill NS
    Chest; 2007 Sep; 132(3):741-3. PubMed ID: 17873184
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review.
    Demerouti EA; Manginas AN; Athanassopoulos GD; Karatasakis GT; Leontiadis ED; Pavlides GS
    Respir Care; 2013 Feb; 58(2):e1-5. PubMed ID: 22710078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The globalization of clinical trials in pulmonary arterial hypertension.
    Park MH; Rubin LJ
    J Heart Lung Transplant; 2010 Feb; 29(2):157-8. PubMed ID: 20113908
    [No Abstract]   [Full Text] [Related]  

  • 5. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.
    Suleman N; Frost AE
    Chest; 2004 Sep; 126(3):808-15. PubMed ID: 15364760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    LeVarge BL; Channick RN
    Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treprostinil in pulmonary arterial hypertension: Is the glass half full or half empty?
    Provencher S
    Eur Respir J; 2006 Dec; 28(6):1073-5. PubMed ID: 17138674
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term prostacyclin reduces pulmonary vascular resistance in severe primary pulmonary hypertension.
    Barst RJ
    Clin Exp Rheumatol; 1998; 16(3):253-4. PubMed ID: 9631745
    [No Abstract]   [Full Text] [Related]  

  • 9. Overdosing with prostacyclin in primary pulmonary hypertension.
    Wasserman K; Oudiz R
    J Am Coll Cardiol; 2000 Jun; 35(7):1995-6. PubMed ID: 10841256
    [No Abstract]   [Full Text] [Related]  

  • 10. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension.
    Levy M; Celermajer DS; Bourges-Petit E; Del Cerro MJ; Bajolle F; Bonnet D
    J Pediatr; 2011 Apr; 158(4):584-8. PubMed ID: 21035821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    Poms A; Kingman M
    Crit Care Nurse; 2011 Dec; 31(6):e1-10. PubMed ID: 22135338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining treprostinil and sildenafil in the treatment of pulmonary hypertension.
    Chua R; Keogh A
    Intern Med J; 2005 Nov; 35(11):684-5. PubMed ID: 16248867
    [No Abstract]   [Full Text] [Related]  

  • 13. Treprostinil for pulmonary hypertension.
    Vachiéry JL; Naeije R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
    Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
    J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prostacyclin and iloprost in aerosol form in severe pulmonary hypertension].
    Olschewski H; Walmrath D; Schermuly R; Ghofrani HA; Grimminger F; Seeger W
    Pneumologie; 1998 Jan; 52(1):3-7. PubMed ID: 9540363
    [No Abstract]   [Full Text] [Related]  

  • 16. [The first LENUS pro® pump implantation in Poland in patient with pulmonary hypertension].
    Pawlak A; Koteja A; Starska A; Kurzyna M; Gil RJ
    Kardiol Pol; 2016; 74(3):300. PubMed ID: 27004544
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right-heart dysfunction, and refractory hypoxemia after cardiothoracic surgery.
    Muzaffar S; Shukla N; Angelini GD; Jeremy JY
    J Thorac Cardiovasc Surg; 2004 Dec; 128(6):949-50. PubMed ID: 15573083
    [No Abstract]   [Full Text] [Related]  

  • 18. Infections by gram-negative bacilli in patients with pulmonary arterial hypertension treated with intravenous prostacyclin.
    Gómez Sánchez MA
    Arch Bronconeumol; 2013 Mar; 49(3):128-9. PubMed ID: 23127721
    [No Abstract]   [Full Text] [Related]  

  • 19. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
    Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
    Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The "bouncing" catheter.
    Malaczynska-Rajpold K; Kurzyna M; Koteja A; Torbicki A; Mularek-Kubzdela T
    Cardiol J; 2016; 23(5):552-553. PubMed ID: 27723062
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.